Kristi Elkins

1.2k total citations
8 papers, 273 citations indexed

About

Kristi Elkins is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Geriatrics and Gerontology. According to data from OpenAlex, Kristi Elkins has authored 8 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Geriatrics and Gerontology. Recurrent topics in Kristi Elkins's work include Monoclonal and Polyclonal Antibodies Research (4 papers), CAR-T cell therapy research (3 papers) and PARP inhibition in cancer therapy (3 papers). Kristi Elkins is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), CAR-T cell therapy research (3 papers) and PARP inhibition in cancer therapy (3 papers). Kristi Elkins collaborates with scholars based in United Kingdom and United States. Kristi Elkins's co-authors include Yang Xiao, Thomas O’Brien, Lisa D. Belmont, Andrew G. Polson, Bing Zheng, Allen Ebens, Shang‐Fan Yu, Bianca M. Liederer, Xiaorong Liang and Jacqueline McBride and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Kristi Elkins

8 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kristi Elkins United Kingdom 5 174 105 103 68 51 8 273
Alexander Lifke Germany 4 283 1.6× 17 0.2× 152 1.5× 46 0.7× 6 0.1× 5 424
Francesca Avogadri-Connors United States 9 175 1.0× 10 0.1× 120 1.2× 21 0.3× 27 0.5× 15 314
Cinzia Bologna Italy 9 101 0.6× 17 0.2× 131 1.3× 4 0.1× 50 1.0× 17 303
Elena Martínez‐Terroba United States 9 70 0.4× 49 0.5× 301 2.9× 12 0.2× 4 0.1× 13 431
Veronika Brychtová Czechia 11 105 0.6× 3 0.0× 222 2.2× 11 0.2× 14 0.3× 20 376
Judith C. Sporn United States 11 170 1.0× 6 0.1× 411 4.0× 6 0.1× 10 0.2× 13 511
Kevin Watanabe‐Smith United States 9 69 0.4× 11 0.1× 145 1.4× 9 0.1× 13 267
Dejan Radeski Australia 9 140 0.8× 2 0.0× 164 1.6× 12 0.2× 3 0.1× 20 307
Jeroen Lammerts van Bueren Netherlands 7 161 0.9× 1 0.0× 102 1.0× 51 0.8× 59 1.2× 22 290

Countries citing papers authored by Kristi Elkins

Since Specialization
Citations

This map shows the geographic impact of Kristi Elkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristi Elkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristi Elkins more than expected).

Fields of papers citing papers by Kristi Elkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristi Elkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristi Elkins. The network helps show where Kristi Elkins may publish in the future.

Co-authorship network of co-authors of Kristi Elkins

This figure shows the co-authorship network connecting the top 25 collaborators of Kristi Elkins. A scholar is included among the top collaborators of Kristi Elkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristi Elkins. Kristi Elkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Wang, Weiru, Kristi Elkins, Angela Oh, et al.. (2014). Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors. PLoS ONE. 9(10). e109366–e109366. 30 indexed citations
2.
Shames, David S., Kristi Elkins, Kimberly Walter, et al.. (2013). Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. Clinical Cancer Research. 19(24). 6912–6923. 59 indexed citations
3.
Xiao, Yang, Kristi Elkins, Jenni Durieux, et al.. (2013). Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618. Neoplasia. 15(10). 1151–IN23. 64 indexed citations
4.
Elkins, Kristi, Bing Zheng, MaryAnn Go, et al.. (2012). FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics. 11(10). 2222–2232. 69 indexed citations
5.
Dornan, David, Bart Burington, Yue Peng, et al.. (2009). CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.. Blood. 114(22). 2721–2721. 1 indexed citations
6.
Polson, Andrew G., Bing Zheng, Kristi Elkins, et al.. (2009). FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.. Blood. 114(22). 3836–3836. 4 indexed citations
7.
Zheng, Bing, Reina N. Fuji, Kristi Elkins, et al.. (2009). In vivoeffects of targeting CD79b with antibodies and antibody-drug conjugates. Molecular Cancer Therapeutics. 8(10). 2937–2946. 42 indexed citations
8.
Polson, Andrew G., Fiona Bennett, Yvonne Chen, et al.. (2008). Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma. Blood. 112(11). 2618–2618. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026